Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of [64Cu]FBP8 for PET-MR Imaging of Thrombosis
NCT03830320Phase 1Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2016
- Primary completion
- Jan 2027
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of [64Cu]FBP8 in thrombosis (5 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Complete blood count at 36 hours, Target to Background Ratio LAA at 4 hours and 2 more. Started Apr 2016; status: recruiting.
02
Drugs
[64Cu]FBP8
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT03830320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03830320.